Search clinical trials for: Neurotransmitter Uptake Inhibitors

Total 79625 results

Weill Medical College of Cornell University

Recruiting

Impact of Escitalopram on Sperm DNA Fragmentation

Infertility, Male | Sperm DNA Fragmentation

United States
University of Pennsylvania

Completed

SSRI Effects on Depression and Immunity in HIV/AIDS

Depression | HIV | AIDS

United States
All India Institute of Medical Sciences, Bhubaneswar

Completed

Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder

Major Depressive Disorder

India
University of Calgary

Recruiting

Study of Atomoxetine in the Prevention of Vasovagal Syncope (POST7)

Vasovagal Syncope

Canada
Lindner Center of HOPE
University of Cincinnati

Completed

Atomoxetine in the Treatment of Binge Eating Disorder

Binge-eating Disorder

United States
Eli Lilly and Company

Completed

Safety Study in Outpatient Japanese Children With ADHD

Attention Deficit Hyperactivity Disorder

Japan
Eli Lilly and Company

Completed

A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD

Attention Deficit Hyperactivity Disorder

Netherlands
Zogenix International Limited, Inc., a subsidiary...

Terminated

A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome

Dravet Syndrome

United States
NYU Langone Health

Completed

Fenfluramine in CDKL5 Deficiency Disorder (CDD)

CDD

United States
Eli Lilly and Company

Completed

Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.

Attention Deficit Hyperactivity Disorder

Canada
William Ondo, MD
H. Lundbeck A/S

Recruiting

A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)

Huntington's Disease

United States
National Institute on Drug Abuse (NIDA)
University of Pennsylvania

Completed

Atomoxetine for the Treatment of Cannabis Dependence

Cannabis Dependence

United States
Eli Lilly and Company

Completed

Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)

ADHD

United States
Eli Lilly and Company

Completed

Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine

Attention Deficit Hyperactivity Disorder

Canada, United States
Eli Lilly and Company

Completed

Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD

Attention-Deficit/Hyperactivity Disorder | Comorbid Dyslexia

United States
Eli Lilly and Company

Completed

Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

Attention-Deficit/Hyperactivity Disorder

Canada
Eli Lilly and Company

Completed

Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Canada
University of Texas Southwestern Medical Center

Not yet recruiting

Escitalopram in Asthma Patients With Frequent Exacerbation

Asthma

United States
Zogenix, Inc.
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

Active, not recruiting

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

Dravet Syndrome | Epileptic Encephalopathy | Lennox Gastaut Syndrome

United States, Australia, Belgium, Canada, Denmark, France, Germany, Italy, Mexico, Netherlands, Poland, Spain, Sweden, United Kingdom
Zogenix, Inc.

Approved for marketing

ZX008 Expanded Access Protocol

Dravet Syndrome
New York State Psychiatric Institute
National Institute of Mental Health (NIMH)

Completed

Antidepressant Treatment of Melancholia in Late Life

Depression | Melancholia

United States
National Institute on Drug Abuse (NIDA)

Completed

Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals

Marijuana Abuse

United States
Temple University

Terminated

Tricyclic Antidepressants (TCAs) on Gastric Emptying

Dyspepsia

United States
National Institute of Mental Health (NIMH)

Completed

Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression

Depressive Disorder | Bipolar Disorder

United States
Samsung Medical Center

Completed

Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients

Overactive Bladder

Korea, Republic of
University of California, Los Angeles

Available

Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol) (Dravet)

Dravet Syndrome

United States
Cephalon

Completed

A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States
Eli Lilly and Company

Completed

Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD

Attention Deficit Hyperactivity Disorder

Taiwan
Eli Lilly and Company

Completed

Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Disorder With Hyperactivity

Russian Federation
Prestwick Pharmaceuticals

Completed

Efficacy and Safety of Tetrabenazine in Chorea

Huntington's Disease
First Affiliated Hospital of Chongqing Medical...

Completed

Efficacy and Safety of Sertraline in the Treatment of Maintenance Hemodialysis Patients With Depression

Adverse Reaction to Drug | Efficacy, Team

China
BC Women's Hospital & Health Centre

Completed

Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine

Depression

Canada
Hamilton Health Sciences Corporation
St. Joseph's Healthcare Hamilton; Wyeth is now a wholly owned subsidiary of... and other collaborators

Unknown

Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women (DVS)

Major Depressive Disorder | Menopausal Staging and Vasomotor Symptoms (for Females)

Canada
Kliniken Essen-Mitte
University of Bordeaux; German Federal Ministry of Education and Research; Ruhr... and other collaborators

Completed

The Role of Inflammatory Processes in Development and Treatment of Depression (INFLAME-D)

Depressive Disorder | Depression | Inflammation
Poitiers University Hospital

Terminated

Atomoxetine in Patients With Tourette's Syndrome (ATO-TS)

Tourette Syndrome

France
Joseph Jankovic

No longer available

Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements (TBZ)

Hyperkinetic Movement Disorders
NYU Langone Health
Eli Lilly and Company

Completed

Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility

Attention Deficit Hyperactivity Disorder
Yale University
National Institute on Drug Abuse (NIDA)

Completed

Atomoxetine Effects in Humans

Physiological Stress
Peking University

Unknown

Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

China
Central Institute of Mental Health, Mannheim
Heidelberg University

Completed

Driving in Adults With Attention-deficit/Hyperactivity Disorder (ADHD) Before and During Treatment With Atomoxetine (DrivPerfATX)

Attention Deficit Hyperactivity Disorder

Germany
Eli Lilly and Company

Completed

Evaluation of Continuous Symptom Treatment of ADHD

Attention Deficit Hyperactivity Disorder

United States
Eli Lilly and Company

Completed

An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Germany
Eli Lilly and Company

Completed

An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Germany
Eli Lilly and Company

Completed

Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD

Attention-Deficit/Hyperactivity Disorder

United States
Rhode Island Hospital
Eli Lilly and Company

Unknown

Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents

Insomnia | Attention-Deficit/Hyperactivity Disorder (ADHD)

United States
Apnimed

Completed

Trial of AD113 and Atomoxetine in OSA Patients With Hypertension

Hypertension | Obstructive Sleep Apnea

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

Marijuana Abuse | Attention Deficit Disorder With Hyperactivity

United States
Cephalon

Completed

Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.

Anxiety Disorders

United States, Canada
Massachusetts General Hospital
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)

Withdrawn

Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD

Substance Use Disorder | Attention Deficit Hyperactivity Disorder

United States
Monarch Medical Research
Eli Lilly and Company

Terminated

Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL

Attention Deficit Hyperactivity Disorder

United States

Search clinical trials for: Neurotransmitter Uptake Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations